Christopher Benecchi - Jun 16, 2022 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Commercial Officer
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Christopher Benecchi
Stock symbol
SAGE
Transactions as of
Jun 16, 2022
Transactions value $
$0
Form type
4
Date filed
6/21/2022, 04:02 PM
Previous filing
Feb 15, 2022
Next filing
Feb 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Options (Right to buy) Award $0 +9.5K $0.00 9.5K Jun 16, 2022 Common Stock 9.5K $31.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded on June 16, 2022 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 2,375 shares of common stock shall vest on the one year anniversary of June 16, 2022, with 7,125 options vesting in 36 equal monthly installments thereafter.